|
By: Holly Murphy, MS, RD, LDN, IBCLC
Ozempic, Wegovy, and Mounjaro are FDA-approved drugs initially designed to treat type II diabetes. Of the three, Wegovy is specifically approved by the FDA for chronic weight-loss management. These drugs, as well as their less pricey, non-brand-name equivalent– compounded semaglutide, which may be manufactured through state-licensed compounding pharmacies across the US – belong to a class of pharmaceuticals called glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs, as you’ve surely heard if you’ve opened any social media app in the last year, have been shown to lead to weight-loss as a side effect, by acting to suppress appetite, slow the rate at which the stomach empties, and to control blood sugar.
Unfortunately, studies have shown that most individuals gain a significant portion of this weight back a year after discontinuing use of these drugs [1]. Therefore, prior to initiating use with weight-loss as the goal, it is essential that you work with a dietitian or other qualified healthcare professional to plan out your “exit strategy.” In other words, how will you maintain your weight once you reach your goal and eventually discontinue use of these drugs?
Read the rest of the article on our website!
| 
